CHANAKYA NATIONAL LAW UNIVERSITY‚ PATNA Economics-II Project on:- IPR and access to medicines in india Submitted To: Mrs. Shivani Mohan (Faculty for Economics) Submitted By: Somya Priyadarshini Roll No.: 471 Semester: IVth ‚ 2nd Year. ACKNOWLEDGEMENT The present project
Premium Patent Patent law Pharmaceutical industry
Executive Summary The effects of globalization are prevalent in almost all industries world-wide; the pharmaceutical industry is no exception. Through the globalization of markets and production‚ there has been a dramatic shift in the last several years. Eli Lilly is a leading company in the US and throughout the world‚ and they’ve had to adapt to the trends that come as a result of globalization including moving operations overseas and capitalizing on advantages present in other markets. The
Premium India Pharmaceutical industry
Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
research-based biomedical and pharmaceutical company (Pfizer 2009‚ p.2). To ensure continuous improvement in all areas of the organization‚ leadership believes in the effectiveness of proper training. Having training based programs allows employees to gain new knowledge‚ exchange ideas‚ and search for answers to his or her concerns or issues. According to McGlynn (1998)‚ Pfizer is a knowledge business. It is not enough to just discover and develop new pharmaceutical products. Employees have to be
Premium Pharmaceutical industry Human resource management Employment
techniques. In conclusion‚ I will recommend a buy or sell option and a target price based on all analysis and data provided. THE INDUSTRY AND OUTLOOK Competitive forces in the pharmaceutical industry: Monopolistic competitive One of the fastest growing industries (healthcare and pharmaceuticals) A lot of generic brand competition‚ but this can be combated with discount coupons Multiple companies that produce drugs No one company has control of the industry Most companies don’t
Premium Pharmaceutical industry Stock Investment
final approval by USFDA to make cheaper versions of Valcyte. The company is expected to launch the drug shortly in the US market. ROC questions Plethico Pharmaceuticals over complaints from investors on the fixed deposit schemes The Registrar of Companies (ROC)‚Gwalior is inspecting the books of accounts of the Indore-based Plethico Pharmaceuticals‚ following hundreds of complaints received by the investor grievance cell of the corporate affairs ministry for almost a year. The investors claimed that
Premium Food and Drug Administration Generic drug Pharmaceutical industry
GLAXOSMITHKLINE PHARMACEUTICALS GlaxoSmithKline plc is a global healthcare group engaged in the creation‚ discovery‚ development‚ manufacture and marketing of pharmaceutical and consumer health related products. The company operated in two segments: Pharmaceuticals (Prescription pharmaceuticals and vaccines)‚ and Consumer Healthcare. STRATEGIC BUSINESS UNIT – PHARMACEUTICALS MANUFACTURING AND MARKETING STRATEGIC GROUP FOR THE SBU – CONTRACT MANUFACTURING Company Information &
Premium Pharmaceutical industry
|7 | |4 |PHARMA INDUSTRY TODAY |7 | |5 |KEY ISSUE FOR PHARMACEUTICAL INDUSTRY |8 | |6 |INDUSTRY SEGMENTATION
Premium Pharmaceutical industry Pharmacology Generic drug
HOW SUPPLY CHAIN VISIBILITY CAN CHANGE THE FACE OF CLINICAL TRIALS October 2012 When it comes to clinical trials‚ many pharmaceutical companies seem to be lacking something. Opportunities to make financial and time saving benefits are not being taken. And yet easy to initiate solutions are now available that can affect genuine change. Often discussed but rarely seen in action‚ clinical trials supply chain visibility looks set to significantly improve the entire clinical trials process. Everything
Premium Clinical trial Pharmaceutical industry Clinical research
Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development